

**University of Texas Health Science Center at San Antonio  
Institutional Biosafety Committee (IBC)  
Microsoft Teams MINUTES OF MEETING  
August 12, 2025**

**Members attending the meeting:** Bieniek, Kevin; Chatterjee, Bandana; Chen, Ching-Kang Jason; Elliott, James; Ginsburg, Brett; Gould, Georgianna; Martinez-Sobrido, Luis;; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Charlton, Michael - voting)

**Guests Present:** Rincon, Erica; Melendez, Griselda; Barlett, Emily; Vasquez, Rebecca.

**Absent members:** Charlton, Michael; Burgin, Tiffani; Dallas, Steven; Gauduin, Marie Claire; Mishra, Bibhuti; Shio, Yuzuru; Vogel, Kristine.

**1. Panel Chair Announcement**

The meeting was called to order at 11:01 a.m. by the IBC Chair, Dr. Yan Xiang. A quorum was established.

**2. Confidentiality of Panel Proceedings and Conflict of Interest**

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

**3. Approval of minutes from the previous meeting**

The Committee approved the minutes as written from the July 08, 2025, IBC meeting.

**Approved** (14 voted to approve, 0 opposed, 0 abstained)

**4. Review of Approved Protocols-** The spreadsheet of approved protocols will be sent out for review in December 2025.

**5. Old Business –**

**6. Educational Items – None**

**7. Occupational Medicine- None**

**8. Other –**The updated Biological Safety Handbook was reviewed and approved.

**9. Review of EHS Assistant-  
10. Meeting Reminder**

The next meeting will be held on September 09, 2025.

**Protocols for Review**

**11. Presentation, Discussion, and Voting on an Initial Protocol:**

**Protocol ID:** 0000020267

**Principal Investigator:** Zhu, YI; Barshop

**Title:** N/A

**Review Type:** Full Committee Review

**Form Type:** Initial

**Approved** (13 voted to approve, 0 opposed, 1 abstained)

Initial application to work with human primary cells and human cell line IMR-90 at BSL-2 containment. Work with recombinant C3a peptide, siRNA. mouse blood, mouse urine, mouse brain tissue, and mouse primary preadipocytes at BSL-1 containment.

In vivo:

Work with recombinant C3a peptide and mouse primary preadipocytes in transgenic and knock-out mice at ABSL-1 containment.

IACUC# IPROTO202500000063

*Protocol does include the use of recombinant DNA.*

This protocol was approved with clarification

1. The committee requested clarification on biological agents and their source stated in the summary.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

*Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

**12. Presentation, Discussion, and Voting on an Amendment Protocol:**

**Protocol ID:** 0000019978

**Principal Investigator:** Rasmussen, Blake; Cellular & Integrative Physiology

**Title:** N/A

**Review Type:** Full Review

**Form Type:** Amendment

**Approved** (14 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with AAV plasmids (AAV.TBG.PI.Cre.rBG, and pAAV.TBG.PI.Null.bGH) at BSL-1 containment. Work with knock-out mice strains (TMEM94/TMEM94, Mrs2/Mrs2-floxed, HDC/HDC-flox) and transgenic mice strains (Liver-Specific Cre, Thy1-aSynLine 61) at ABSL-1. IACUC #2024003AR.

In vivo:

Work with AAV plasmids (AAV.TBG.PI.Cre.rBG, and pAAV.TBG.PI.Null.bGH) in knock-out and transgenic mice at ABSL-1 containment.

IACUC# 20240003AR

*Protocol does include the use of recombinant DNA.*

This protocol was approved with clarification.

1. The committee members requested additional information on the injection procedure and the experience of the lab members performing the procedure.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

### **13. Presentation, Discussion, and Voting on a Renewal Protocol:**

**Protocol ID:** 0000020213

**Principal Investigator:** Lechleiter, James; Cell Systems & Anatomy

**Title:** N/A

**Review Type:** Full Review

**Form Type:** Renewal

**Approved** (14 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with Adenovirus, Ecotropic retrovirus, replication-incompetent Lentivirus, HEK293, human tissue, lentiviral vectors (pUltra, pUltra-hot, pVETL-ICK GFP, pMD@, psPAX2, psMPuq-promoterless, pLox-tert, pLox w cre, pLox qfpire, pHelper, pLX301, mEon3.2-N1, pENTR1A, pET32, pEntr-DTopo, pcDNA4/myc-His, pCW57.1, pcDNA3.1-SARS2-Spike, pcDNA3.1-SARS1-Spike), Retroviral vectors (pBABEpuro, pCL-Eco, pSH, pET28a, pET-Duet, pBS185, pET-mCherry-Lic) at BSL-2 containment. Work with E. coli (lab strains), Adeno-associated virus, vectors (pCDNA, pGEM Teasy, pGEX-6P1, pT3678, pT3719, pT4066-5Ad5), and AAV vector (pAAV-RC2) at BSL-1 containment.

In vivo:

Work with Adeno-associated virus in knock-out and transgenic mice at ABSL-1 containment.

IACUC# 08042X, 14057X

Work with replication-incompetent Lentivirus in knock-out and transgenic mice at ABSL-2 containment.

IACUC# 08042X, 14057X

*Protocol does include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

*Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2*

*Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1*

*Cloning and vector construction in bacteria and yeasts. III-E, III-F*

*Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

*Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4*

#### **14. Presentation, Discussion, and Voting on a Renewal Protocol:**

**Protocol ID:** 0000020144

**Principal Investigator:** Gonzales, Cara; Comprehensive Dentistry

**Title:** None

**Review Type:** Full Review

**Form Type:** Renewal

**Approved** (14 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with human cell lines (CAL27, HSC3, SCC-15, SCC-25, SCC-4, SCC-9, MCF-7, HELA, MDA-231, PC3, OSCC) at BSL-2 containment. Work with T3 Bacteriophage and mouse blood at BSL-1 containment.

In vivo:

Work with human cell lines (CAL27, HSC3, SCC-15, SCC-25, SCC-4, SCC-9, MCF-7, HELA, MDA-231, PC3, OSCC) in mice at ABSL-2 containment.

IACUC# 13062X, # 09120X

*Protocol does include the use of recombinant DNA*

This protocol was approved as written.


*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*


Adjourn: The meeting adjourned at 11:54 A.M.

---



---

Dr. Yan Xiang  
Institutional Biosafety Committee Chair  
University of Texas Health San Antonio



---

Dorothy Macias  
Recorder, Institutional Biosafety Committee  
University of Texas Health San Antonio

dam